DCBs, which are also known as DEBs, are innovative and long-awaited transcatheter technology that is recently introduced in the market to help reduce high restenosis rates in PAD and CAD. DCBs are standard (semi-compliant) angioplasty balloon catheters coated with a cytotoxic chemotherapeutic agent. The device is covered/coated with an anti-proliferative drug, which is released into the blood vessel wall during inflation of the device. These devices have been developed recently to overcome a few major limitations of DES such as high ISR and revascularization rates. There is an established indication for the use of DCB in the treatment of instent restenosis (ISR), and they are also invariably used in several setting, particularly small coronary vessels and bifurcations.

1 RESEARCH METHODOLOGY 

2 RESEARCH OBJECTIVES 

3 RESEARCH PROCESS 

4 REPORT COVERAGE 

5 REPORT ASSUMPTIONS & CAVEATS 

6 MARKET AT A GLANCE 

7 INTRODUCTION 

8 MARKET DYNAMICS

9 GLOBAL DRUG-COATED BALLOONS MARKET 

10 BY INDICATION 

11 BY END-USERS 

12 BY GEOGRAPHY

13 NORTH AMERICA

14 EUROPE 

15 APAC 

16 REST OF THE WORLD 

17 COMPETITIVE LANDSCAPE 

18 KEY COMPANY PROFILES

19 KEY COMPANIES TO WATCH

20 OTHER PROMINENT VENDORS

21 REPORT SUMMARY 

22 APPENDIX